Anthony Slavin

4.7k total citations
53 papers, 3.6k citations indexed

About

Anthony Slavin is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Anthony Slavin has authored 53 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Immunology, 18 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Anthony Slavin's work include T-cell and B-cell Immunology (17 papers), Immunotherapy and Immune Responses (14 papers) and Immune Cell Function and Interaction (10 papers). Anthony Slavin is often cited by papers focused on T-cell and B-cell Immunology (17 papers), Immunotherapy and Immune Responses (14 papers) and Immune Cell Function and Interaction (10 papers). Anthony Slavin collaborates with scholars based in United States, Australia and Germany. Anthony Slavin's co-authors include Scott S. Zamvil, Claude C.A. Bernard, Howard L. Weiner, Jayaram Bettadapura, Ruth Maron, Juan C. Patarroyo, Timothy Hoey, Michael W. Marino, Lloyd J. Old and Ashley R. Dunn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Anthony Slavin

51 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anthony Slavin United States 28 1.9k 1.1k 986 617 407 53 3.6k
Jingwu Z. Zhang China 32 2.0k 1.1× 776 0.7× 852 0.9× 671 1.1× 662 1.6× 50 3.6k
Stefan Brocke United States 36 2.9k 1.6× 930 0.9× 1.2k 1.2× 1.2k 2.0× 590 1.4× 76 5.2k
B. Cannella United States 19 1.8k 1.0× 684 0.6× 635 0.6× 542 0.9× 349 0.9× 28 3.0k
Mark Wing United Kingdom 29 1.2k 0.6× 929 0.9× 645 0.7× 452 0.7× 260 0.6× 47 3.0k
Anna Schubart Switzerland 21 2.7k 1.4× 843 0.8× 1.2k 1.3× 1.1k 1.8× 183 0.4× 38 4.1k
David O. Willenborg Australia 32 1.9k 1.0× 671 0.6× 668 0.7× 597 1.0× 311 0.8× 77 3.2k
M. Schmied Austria 16 1.0k 0.5× 614 0.6× 977 1.0× 337 0.5× 184 0.5× 24 2.7k
David E. Szymkowski United States 33 1.0k 0.6× 339 0.3× 1.5k 1.5× 509 0.8× 265 0.7× 66 3.5k
Dvora Teitelbaum Israel 34 2.2k 1.2× 2.0k 1.9× 684 0.7× 588 1.0× 497 1.2× 70 4.1k
Robert H. Swanborg United States 29 1.7k 0.9× 532 0.5× 617 0.6× 460 0.7× 257 0.6× 87 2.7k

Countries citing papers authored by Anthony Slavin

Since Specialization
Citations

This map shows the geographic impact of Anthony Slavin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Slavin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Slavin more than expected).

Fields of papers citing papers by Anthony Slavin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Slavin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Slavin. The network helps show where Anthony Slavin may publish in the future.

Co-authorship network of co-authors of Anthony Slavin

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Slavin. A scholar is included among the top collaborators of Anthony Slavin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Slavin. Anthony Slavin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Enerson, Bradley E., Gregg D. Cappon, Yatao Shi, et al.. (2025). Developmental toxicology profile of the IRAK4 degrader KT-474. Toxicological Sciences. 209(2).
2.
Agarwal, Sagar, Alice McDonald, Dapeng Chen, et al.. (2025). Pharmacokinetics and Pharmacodynamics of KT‐474, a Novel Selective Interleukin‐1 Receptor–Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults. Clinical and Translational Science. 18(3). e70181–e70181. 4 indexed citations
3.
McDonald, Alice, Rahul Karnik, Veronica A. Campbell, et al.. (2024). IRAK4 Is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers. Journal of Investigative Dermatology. 145(2). 323–333.e10. 5 indexed citations
4.
Slavin, Anthony, Veronica A. Campbell, Michele Mayo, et al.. (2020). 588 Identification of highly potent and selective Interleukin-1 receptor associated kinase 4 (IRAK4) degraders for the treatment of hidradenitis suppurativa. Journal of Investigative Dermatology. 140(7). S80–S80. 1 indexed citations
5.
Molnarfi, Nicolas, Ulf Schulze‐Topphoff, Martin S. Weber, et al.. (2013). MHC class II–dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. The Journal of Experimental Medicine. 210(13). 2921–2937. 318 indexed citations
6.
7.
Gao, Feng, Bo Liu, Alana Althage, et al.. (2010). Transient expression of an IL-23R extracellular domain Fc fusion protein in CHO vs. HEK cells results in improved plasma exposure. Protein Expression and Purification. 71(1). 96–102. 32 indexed citations
8.
Weber, Martin S., Thomas Prod’homme, Juan C. Patarroyo, et al.. (2010). B‐cell activation influences T‐cell polarization and outcome of anti‐CD20 B‐cell depletion in central nervous system autoimmunity. Annals of Neurology. 68(3). 369–383. 247 indexed citations
9.
Slavin, Anthony, et al.. (2010). Pathogenic mechanisms and experimental models of multiple sclerosis. Autoimmunity. 43(7). 504–513. 39 indexed citations
10.
Horst, Edward H. van der, Brendon Frank, Lawrence Chinn, et al.. (2008). The Growth Factor Midkine Antagonizes VEGF Signaling In Vitro and In Vivo. Neoplasia. 10(4). 340–IN3. 31 indexed citations
11.
Stremmel, Christian, Wulf Sienel, Stephan Eggeling, Bernward Passlick, & Anthony Slavin. (2006). Inhibition of T cell homing by down-regulation of CD62L and the induction of a Th-2 response as a method to prevent acute allograft rejection in mice☆. European Journal of Cardio-Thoracic Surgery. 30(2). 362–369. 8 indexed citations
12.
Stremmel, Christian, et al.. (2005). Characterization of gene expression profiles of T cells during anti-tumor response. International Journal of Colorectal Disease. 20(6). 485–493. 1 indexed citations
13.
Tarner, Ingo H., Anthony Slavin, Jacqueline McBride, et al.. (2003). Treatment of Autoimmune Disease by Adoptive Cellular Gene Therapy. Annals of the New York Academy of Sciences. 998(1). 512–519. 34 indexed citations
14.
Costa, Gina L., Atsuo Nakajima, Cariel Taylor-Edwards, et al.. (2001). Adoptive Immunotherapy of Experimental Autoimmune Encephalomyelitis Via T Cell Delivery of the IL-12 p40 Subunit. The Journal of Immunology. 167(4). 2379–2387. 145 indexed citations
15.
16.
Spahn, Thomas W., A. Fontana, Ana Maria Caetano Faria, et al.. (2001). Induction of oral tolerance to cellular immune responses in the absence of Peyer's patches. European Journal of Immunology. 31(4). 1278–1287. 115 indexed citations
17.
18.
Inobe, Jun-ichi, Anthony Slavin, Yoshinori Komagata, et al.. (1998). IL-4 is a differentiation factor for transforming growth factor-β secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. European Journal of Immunology. 28(9). 2780–2790. 178 indexed citations
19.
Slavin, Anthony, Christine Ewing, Junliang Liu, et al.. (1998). Induction of a Multiple Sclerosis-Like Disease in Mice with an Immunodominant Epitope of Myelin Oligodendrocyte Glycoprotein. Autoimmunity. 28(2). 109–120. 118 indexed citations
20.
Bernard, Claude C.A., Terrance G. Johns, Anthony Slavin, et al.. (1997). Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. Journal of Molecular Medicine. 75(2). 77–88. 220 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jingwu Z. Zhang Breakdown of academic impact, for papers by Stefan Brocke Breakdown of academic impact, for papers by B. Cannella Breakdown of academic impact, for papers by Mark Wing Breakdown of academic impact, for papers by Anna Schubart Breakdown of academic impact, for papers by David O. Willenborg Breakdown of academic impact, for papers by M. Schmied Breakdown of academic impact, for papers by David E. Szymkowski Breakdown of academic impact, for papers by Dvora Teitelbaum Breakdown of academic impact, for papers by Robert H. Swanborg
Rankless by CCL
2026